• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Equillium Inc. filed SEC Form 8-K: Other Events

    9/4/25 4:01:28 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EQ alert in real time by email
    8-K
    false000174646600017464662025-08-292025-08-29

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): August 29, 2025

    Equillium, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

    Delaware

    001-38692

    82-1554746

    (State or Other Jurisdiction

    of Incorporation)

    (Commission

    File Number)

    (IRS Employer

    Identification No.)

     

     

    2223 Avenida de la Playa

    Suite 105

    La Jolla, CA

     

     

     

    92037

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (858) 240-1200

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class

    Trading

    Symbol(s)

    Name of each exchange on which registered

    Common Stock, par value $0.0001 per share

    EQ

    The Nasdaq Capital Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     


     

     

    Item 8.01 Other Events.

     

    On August 29, 2025, Equillium, Inc. (the "Company") received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”) for continued inclusion on The Nasdaq Capital Market.

     

    As previously disclosed in the Company’s Current Report on Form 8-K filed on December 13, 2024, the Company received a written notice from Nasdaq on December 13, 2024 notifying the Company that it was not in compliance with the Bid Price Rule because its common stock had failed to meet the $1.00 per share minimum bid price requirement for continued inclusion on The Nasdaq Capital Market. As previously disclosed in the Company’s Current Report on Form 8-K filed on June 13, 2025, the Company received a written notice from Nasdaq on June 12, 2025 notifying the Company that it was granted an additional 180-day period to regain compliance with the Bid Price Rule. To regain compliance with the Bid Price Rule, the Company’s common stock was required to maintain a closing bid price of $1.00 per share or more for at least 10 consecutive business days. This requirement was met on August 28, 2025.

     

     

     

     


     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    EQUILLIUM, INC.

     

     

    Date: September 4, 2025

    By: /s/ Bruce D. Steel

     

    Bruce D. Steel

     

    President and Chief Executive Officer

     

     

     

     

     


    Get the next $EQ alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EQ

    DatePrice TargetRatingAnalyst
    3/28/2025$3.00 → $1.00Outperform → Market Perform
    Leerink Partners
    1/5/2022$18.00 → $14.00Outperform
    SVB Leerink
    10/29/2021$12.00Buy
    Stifel
    9/15/2021$14.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $EQ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on August 29, 2025, the Compensation Committee of Equillium's Board of Directors granted inducement awards consisting of nonstatutory stock options to purchase an aggregate of 150,000 shares of common stock to two new employees under Equillium's 2024 Inducement Plan. The Compensation Committee approved the stock option as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $1.74, Equillium's closing stock price on August 29,

    9/3/25 4:05:00 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Equillium to Participate in the Cantor Global Healthcare Conference 2025

    Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the Cantor Global Healthcare Conference 2025 on Friday, September 5, 2025 at 7:55am ET. Members of the Equillium management team will be available to participate in meetings with investors who are registered to attend the conference. Investors and the general public are invited to listen to a live webcast of the presentation on the Events & Presentations page, located under the Investor Relations section on equilliumbio.com. An archived replay of both presentations will be available

    8/29/25 4:03:00 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Equillium Announces Up to $50 Million Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, into the Clinic

    Financing led by ADAR1 Capital Management and Janus Henderson Investors $30 million up front with the potential to receive an additional $20 million at clinical study initiation Phase 1 clinical study initiation planned mid-2026; data anticipated approximately 6 months thereafter Equillium, Inc. ("Equillium" or the "Company") (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced it has entered into a definitive securities purchase agreement with leading healthcare investors that will provide up to $50 million in gross proceeds to Equillium. The private placement is comprised of (i) an initial upfront fi

    8/11/25 8:30:00 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EQ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Equillium downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded Equillium from Outperform to Market Perform and set a new price target of $1.00 from $3.00 previously

    3/28/25 8:14:37 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVB Leerink reiterated coverage on Equillium with a new price target

    SVB Leerink reiterated coverage of Equillium with a rating of Outperform and set a new price target of $14.00 from $18.00 previously

    1/5/22 6:36:04 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel resumed coverage on Equillium with a new price target

    Stifel resumed coverage of Equillium with a rating of Buy and set a new price target of $12.00

    10/29/21 8:33:13 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EQ
    SEC Filings

    View All

    SEC Form S-8 filed by Equillium Inc.

    S-8 - Equillium, Inc. (0001746466) (Filer)

    9/9/25 5:02:59 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by Equillium Inc.

    S-3 - Equillium, Inc. (0001746466) (Filer)

    9/9/25 5:00:45 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Equillium Inc. filed SEC Form 8-K: Other Events

    8-K - Equillium, Inc. (0001746466) (Filer)

    9/4/25 4:01:28 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EQ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Scientific Officer Connelly Stephen

    4 - Equillium, Inc. (0001746466) (Issuer)

    9/3/25 5:04:34 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Principal Accounting Officer Tom Penny

    4 - Equillium, Inc. (0001746466) (Issuer)

    9/3/25 5:02:46 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Sr. Vice President and COO Zedelmayer Christine

    4 - Equillium, Inc. (0001746466) (Issuer)

    9/3/25 5:00:37 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EQ
    Leadership Updates

    Live Leadership Updates

    View All

    Equillium to be included in the Russell Microcap® Index

    Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it expects to join the Russell Microcap Index at the conclusion of the 2024 Russell annual reconstitution, effective at the open of equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24. The annual Russell reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30, ranking them by total market capitalization. Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and va

    6/12/24 8:00:00 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors

    -Mr. Bradbury has over 35 years of experience leading fast-growing life sciences companies- Persephone Biosciences Inc., a biotechnology company reimagining patient health through the development of microbiome-based medicines, today announced that it has appointed Daniel Bradbury as Chair of the Board of Directors. "We are delighted to welcome Dan to our Board. His appointment reflects the recent progress we have made with our MyBabyBiome™ study of infant gut health, and our near-term plans to commercialize our first product based on the findings. Additionally, Persephone has a further two clinical studies underway, namely our ARGONAUT study of gut microbiome-linked immune modulation in

    10/23/23 8:00:00 AM ET
    $CSTL
    $EQ
    $ICPT
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Equillium Announces Appointment of Barbara Troupin to Board of Directors

    Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced the appointment of Barbara Troupin, M.D., to the Equillium Board of Directors. Dr. Troupin will serve as a member of the Nominating and Corporate Governance Committee of the Board. "We are very happy to welcome Dr. Barbara Troupin to the Equillium Board," said Dan Bradbury, chairman of the board of directors of Equillium. "Her experience building and leading clinical development, medical and regulatory affairs functions, as well as her background in global strategy and medical and com

    3/1/22 8:00:00 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EQ
    Financials

    Live finance-specific insights

    View All

    Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease

    Treatment with itolizumab did not improve complete or overall response rates at Day 29 Itolizumab achieved statistical significance in multiple secondary endpoints demonstrating compelling clinical benefit in longer-term outcomes, including complete response at Day 99, duration of complete response and failure-free survival Breakthrough Therapy designation and meeting requests to discuss potential for Accelerated Approval submitted to FDA, feedback expected during May 2025 Management will host a conference call and webcast today at 8:30 am ET Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics

    3/27/25 7:00:00 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Equillium Maintains Rights to Itolizumab Following Ono Partnership

    Ono Pharmaceutical makes strategic business decision to allow itolizumab option to expire Equillium evaluating accelerating completion of Phase 3 EQUATOR study in aGVHD to Q1 2025 Phase 2 ulcerative colitis study recently completed; topline data expected Q1 2025 Management will host a conference call and webcast today at 8:30 am ET Equillium Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that Ono Pharmaceutical Co., Ltd. (Ono) has made the strategic business decision to allow its option to acquire Equillium's rights to itolizumab

    10/31/24 7:00:00 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab

    Equillium grants Ono an option to purchase rights to itolizumab Equillium to receive an upfront payment of approximately $26.0M (¥3.5B); eligible to receive up to approximately $138.5M (¥18.7B) in option exercise and milestone payments Ono to fund Equillium's continued research and development of itolizumab during the exercise period Conference call and webcast today at 8:30 a.m. ET Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, and Ono Pharmaceutical Co., Ltd. ("Ono"), today announced an option and asset purchase agreement through which Ono gains the exclusive option to

    12/6/22 7:00:00 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EQ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Equillium Inc.

    SC 13G/A - Equillium, Inc. (0001746466) (Subject)

    11/14/24 9:50:36 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Equillium Inc.

    SC 13G - Equillium, Inc. (0001746466) (Subject)

    1/19/24 6:03:46 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Equillium Inc. (Amendment)

    SC 13G/A - Equillium, Inc. (0001746466) (Subject)

    3/3/23 9:27:36 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care